Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 06, 2025 04:30 ET | Source: ITM Isotope Technologies Munich SE

ITM Presents Positive Topline Phase 3 COMPETE Trial Data with n.c.a. 177Lu-edotreotide (ITM-11), a Targeted Radiopharmaceutical Therapy, in Patients with Grade 1 or 2 Gastroenteropancreatic Neuroendocrine Tumors at the ENETS 2025 Conference

Trial met primary endpoint, demonstrating clinically and statistically significant improvement in progression-free survival (PFS) compared to everolimus Median PFS was 23.9 months on n.c.a....
February 25, 2025 05:00 ET | Source: ITM Isotope Technologies Munich SE

ITM to Present Top Line Results from Phase 3 COMPETE Trial with [177Lu]Lu-edotreotide for the Treatment of Grade 1 & Grade 2 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) at European Neuroendocrine Tumor Society (ENETS) Conference

Garching / Munich, February 25 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that it will provide topline data results from its Phase...
February 18, 2025 05:00 ET | Source: ITM Isotope Technologies Munich SE

ITM to Present at Raymond James Private Biotech Symposium

Garching / Munich, February 18, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced its participation in the Raymond James Private Biotech...
February 07, 2025 08:00 ET | Source: ITM Isotope Technologies Munich SE

ITM to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference

Garching / Munich, February 7, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced its participation in Oppenheimer’s 35th Annual Healthcare...
January 28, 2025 05:00 ET | Source: ITM Isotope Technologies Munich SE

ITM Announces Positive Topline Results of Phase 3 COMPETE Trial with ITM-11, a Targeted Radiopharmaceutical Therapy, in Patients with Grade 1 or Grade 2 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Phase 3 clinical trial with ITM-11 met its primary endpoint, demonstrating clinically relevant and statistically significant benefit in Progression-Free Survival (PFS) compared to everolimusITM plans...
January 13, 2025 08:00 ET | Source: ITM Isotope Technologies Munich SE

ITM and Ariceum Therapeutics Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225

Garching / Munich / Berlin, Germany, January 13, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Ariceum Therapeutics (Ariceum), a private biotech...
December 13, 2024 05:00 ET | Source: ITM Isotope Technologies Munich SE

ITM to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Garching / Munich, Germany, December 13, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that its Chief Executive Officer, Dr. Andrew...
November 11, 2024 05:00 ET | Source: ITM Isotope Technologies Munich SE

ITM to Participate in Upcoming Investor Conferences

Garching / Munich, November 11, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced its participation in two upcoming industry investor...
October 24, 2024 05:00 ET | Source: ITM Isotope Technologies Munich SE

ITM, TUM und das TUM Universitätsklinikum unterzeichnen eine neue Rahmenvereinbarung zur Entwicklung innovativer radiopharmazeutischer Krebstherapien

Neufahrn / Garching / München, 24. Oktober 2024 – ITM Isotope Technologies Munich SE (ITM), ein führendes radiopharmazeutisches Unternehmen, die Technische Universität München (TUM) und das TUM...
October 24, 2024 05:00 ET | Source: ITM Isotope Technologies Munich SE

ITM, TUM, and TUM University Hospital Sign New Framework Agreement to Advance Innovative Radiopharmaceutical Cancer Treatments

Neufahrn / Garching / Munich, Germany, October 24, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, the Technical University of Munich (TUM) and the TUM...